The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The approval of Imfinzi was granted based on results from the pivotal ADRIATIC Phase III trial which demonstrated statistically significant and clinically meaningful results for its dual primary ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

It remains to be seen if the data with Keytruda will be strong enough to supplant Imfinzi (durvalumab), which was approved for BTC by the FDA last year on the back of data from the TOPAZ-1 trial ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...